

Supplementary files

**Supplementary Table 1.** Applied HER2 test kits by local pathology laboratories and respective time frames.

Methods Local Pathology	Number of Local Pathologies, Year of Local Testing (Timeframe)
HER2 status by immunohistochemistry (IHC)	
HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody, PATHWAY; Roche Ventana HerceptTest™; DAKO	7 sites, 2006–2018
LDT c-erbB-2 Oncoprotein (HER-2), clone CB11 stained on DAKO Autostainer Plus	2 sites, 2010–2018
	1 site, 2010–2012
In situ hybridization (ISH), in equivocal cases (IHC score 2+)	
Ventana Inform HER-2 Dual ISH DNA Probe Cocktail Assay (Roche)	3 sites, 2011–2018
PathVysion HER-2 DNA Probe Kit (Abbott)	3 sites, 2012–2017
HER2 IQFISH pharmDx - Dako Agilent	1 site, 2011

**Supplementary Table 2.** Comparison HER2 immunohistochemistry results between local and central laboratories.

	<i>n</i> = 183	Local HER2 IHC (%)			
		0	1+	2+	3+
Central HER2 IHC	0 ( <i>n</i> = 43)	35 (81)	5 (12)	2 (5)	1 (2)
	1+ ( <i>n</i> = 91)	51 (56)	19 (21)	17 (19)	4 (4)
	2+ ( <i>n</i> = 13)	5 (38)	0 (0)	3 (24)	5 (38)
	3+ ( <i>n</i> = 36)	1 (3)	1 (3)	4 (11)	30 (83)

IHC: immunohistochemistry.

**Supplementary Table 3.** Comparison of local and central HER2 ISH result.

Central HER2 ISH		<i>n</i> = 41 (%)
Positive	Negative	3 (7)
Positive	Not performed	6 (15)
Negative	Not performed	15 (37)
Not performed	Positive	1 (2)
Not performed	Negative	13 (32)
Positive	Positive	1 (2)
Negative	Negative	2 (5)

ISH: in-situ hybridization.